APA (7th ed.) Citation

Fauvre, A., Machu, M., Merienne, A., Vie, N., Bessede, T., Robin, M., . . . Gongora, C. (2024). STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma. Clinical & Translational Medicine, 14(9), 1. https://doi.org/10.1002/ctm2.70011

Chicago Style (17th ed.) Citation

Fauvre, Alexandra, et al. "STING‐ATF3/type I Interferon Crosstalk: A Potential Target to Improve Anti‐tumour Immunity in Chemotherapy‐treated Urothelial Carcinoma." Clinical & Translational Medicine 14, no. 9 (2024): 1. https://doi.org/10.1002/ctm2.70011.

MLA (9th ed.) Citation

Fauvre, Alexandra, et al. "STING‐ATF3/type I Interferon Crosstalk: A Potential Target to Improve Anti‐tumour Immunity in Chemotherapy‐treated Urothelial Carcinoma." Clinical & Translational Medicine, vol. 14, no. 9, 2024, p. 1, https://doi.org/10.1002/ctm2.70011.